CXXB750A12201 (Recruiting)
a multi center, randomized, double-blind placebo controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety and tolerability of XXB750 in patients with heart failure
- Medicine
- XXB750
- Population
- Heart failure
- Phase
- II
- Starting year
- 2023